Strand Life Sciences launches South Asia's first Olink Explore HT proteomics service, enabling large-scale multi-omics discovery
Bengaluru, May 19
Strand Life Sciences, a subsidiary of Reliance Industries Limited, on Tuesday announced the launch of its advanced proteomics capabilities, powered by Olink Explore HT, marking a key milestone in expanding large-scale multi-omics research in India and South Asia.
Every living cell produces thousands of proteins -- the molecular machines that carry out virtually every biological function in the body, from fighting infection to regulating metabolism. Proteomics is the large-scale study of these proteins: what they are, how many are present, and how their levels shift in health and disease. It tells us what is actually being built and in what quantities -- making it one of the most direct windows into the biology of disease.
Next-generation proteomics platforms have enabled the simultaneous analysis of thousands of proteins from a single, small blood sample. The result is a richer, faster, and far more actionable picture of disease biology -- one that supports more precise treatment selection and the discovery of new drug targets.
According to a Reliance Industries Limited release, Strand has successfully completed a proteomics project for a biopharma partner, involving patients with chronic kidney disease, demonstrating the platform's potential in translational research and clinical studies.
"Olink Explore HT enables the measurement of over 5,400 protein biomarkers from just 2 uL of sample -- roughly one-twenty-fifth of a single drop of blood -- allowing Strand to deliver integrated proteomics, genomics, and clinical insights for advanced research and drug discovery," the release said.
"For pharmaceutical and biotechnology companies, this capability represents a transformational change. Research programmes that once required time-intensive sequential investigation can now be compressed into integrated, large-scale studies. For clinicians and patients, the promise is equally significant," it added.
Biomarkers identified through proteomics can guide treatment decisions with greater confidence and open new frontiers in precision medicine.
Ramesh Hariharan, CEO, Strand Life Sciences, said, "With Olink Explore HT, Strand is bringing one of the world's most advanced proteomics platforms to India and the region. By combining this with established strengths in genomics, bioinformatics, and clinical partnerships, Strand aims to deliver end-to-end multi-omics programmes and enable faster, more impactful discovery. We welcome collaborations with global pharma and biotech partners to accelerate research and development pipelines."
Strand can now support the generation of large, multi-modal datasets across diverse and clinically relevant populations in India, broader South Asia, and West Asia. Through its extensive network of clinical partners, the company enables studies across multiple therapeutic areas, including oncology, nephrology, metabolic diseases, and rare disorders.
With this launch, Strand is engaging with global academic, pharmaceutical, and biotechnology organisations seeking to conduct discovery, validation, and translational research programmes at scale, and is offering: access to over 5,400 protein biomarkers through Olinkâ„¢ Explore HT; seamless integration with genomics and clinical datasets; end-to-end support -- from study design to data analysis and interpretation, and proven expertise in executing large cohort-based studies in diverse populations
With this launch, Strand is engaging with global academic, pharmaceutical, and biotechnology organisations seeking to conduct discovery, validation, and translational research programmes at scale, and is offering -- access to over 5,400 protein biomarkers through Olink Explore HT; seamless integration with genomics and clinical datasets; end-to-end support from study design to data analysis and interpretation; and proven expertise in executing large cohort-based studies in diverse populations.
As global demand for integrated multi-omics data continues to grow, Strand's early adoption of Olink Explore HT positions it as a preferred partner for high-impact discovery programmes, the release stated.
— ANI
Reader Comments
As a researcher in Bengaluru, I'm thrilled about this. Genomics has made huge strides here, but proteomics was lagging behind. This Olink platform will fill that gap. The fact that they've already done work with chronic kidney disease patients shows real-world application. I just hope smaller labs and universities can also access these services at affordable rates. Big step for precision medicine in India! 👍
Very impressive but I hope they focus on diseases specific to our population like tuberculosis, malaria, and tropical diseases. Western pharma often ignores these. Strand should collaborate with Indian medical colleges and ICMR to ensure the research benefits our people directly, not just global biotech companies. Good start though!
South Asia's first? That's huge! 💪 I work in clinical diagnostics and the potential for biomarker discovery is immense. If Strand can integrate this with their existing genomics capabilities, it could revolutionise how we approach cancer and metabolic diseases. Ramesh Hariharan's team seems to have a clear vision. Now we need proper data privacy laws to protect patient information in these large studies.
Good technological advancement. But I wish the announcement included specific timelines for when Indian hospitals and patients can actually benefit from this. The RIL release talks about global pharma partners but what about affordable diagnostics for our own population? We need clarity on costs and access. Still, proud that an Indian company is leading in this space. Jai Hind! 🇮🇳
Great to see Indian companies adopting cutting-edge proteomics tech
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.